Adage Capital Partners
ADVM

Adage Capital Partners’s Adverum Biotechnologies ADVM Stock Holding History

Adage Capital Partners’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-50,000
Closed -$10.4M – 749
2020
Q2 		$10.4M Sell
50,000
-130,000
-72% -$23M 0.03% 517
2020
Q1 		$17.6M Buy
180,000
+80,000
+80% +$9.33M 0.05% 351
2019
Q4 		$11.5M Hold
100,000
– – 0.03% 517
2019
Q3 		$5.45M Sell
100,000
-200,000
-67% -$22.5M 0.01% 621
2019
Q2 		$35.7M Hold
300,000
– – 0.09% 257
2019
Q1 		$15.7M Hold
300,000
– – 0.04% 442
2018
Q4 		$9.45M Hold
300,000
– – 0.03% 518
2018
Q3 		$18.1M Sell
300,000
-100,000
-25% -$5.62M 0.04% 423
2018
Q2 		$21.2M Buy
400,000
+50,000
+14% +$3.01M 0.05% 384
2018
Q1 		$20.3M Buy
350,000
+100,000
+40% +$6.23M 0.05% 392
2017
Q4 		$8.75M Buy
250,000
+50,000
+25% +$1.65M 0.02% 584
2017
Q3 		$7.3M Hold
200,000
– – 0.02% 595
2017
Q2 		$5M Buy
+200,000
New +$5.47M 0.01% 634
2015
Q1 		– Sell
-64,955
Closed -$35.1M – 707
2014
Q4 		$35.1M Sell
64,955
-8,166
-11% -$3.15M 0.09% 289
2014
Q3 		$25M Buy
+73,121
New +$21.8M 0.06% 341

Other funds holding ADVM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Adage Capital Partners's ADVM Position: Q3 2020 in Review

Adage Capital Partners sold out of Adverum Biotechnologies (ADVM) in Q3 2020, closing a stake of 50,000 shares — an estimated $10.4M sold.

Adage Capital Partners first reported a position in ADVM in Q3 2014 and held it in 15 quarters. The position peaked at $35.7M in Q2 2019. 160 funds tracked by Wall St. Rank hold ADVM as of Q3 2020.

  • Adage Capital Partners reported no remaining Adverum Biotechnologies position as of Q3 2020 after selling out during the quarter.
  • Adage Capital Partners sold 50,000 Adverum Biotechnologies shares in Q3 2020, an estimated $10.4M.
  • Adage Capital Partners first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 15 quarters.
  • Adage Capital Partners's Adverum Biotechnologies position peaked at $35.7M in Q2 2019.
  • 160 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2020.

Based on Adage Capital Partners's 13F filing for Q3 2020, filed 16 Nov 2020.